Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide (Q46019744)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 15, 2010

Language	Label	Description	Also known as
English	Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide	scientific article published on November 15, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide (English)

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

1 reference

based on heuristic

inferred from title

lupus nephritis

1 reference

based on heuristic

inferred from title

author name string

Maria Dall'Era

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

David Stone

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

Victoria Levesque

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

Miriam Cisternas

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

David Wofsy

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21080348

27 August 2024

publication date

15 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Facr.20397

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.20397/fullpdf

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Arthritis Care and Research

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

63

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

351-357

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis

1

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

2

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

3

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

4

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

6

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide

7

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

9

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

10

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

11

1 reference

10.1002/ACR.20397

https://api.crossref.org/works/10.1002/ACR.20397

27 August 2024

Identifiers

10.1002/ACR.20397

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21080348

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46019744&oldid=2237711341"